Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Sanofi's top-selling insulin treatment Lantus may slow the build-up of artery-clogging deposits, although the benefits are modest, researchers said on Monday.
Lantus, which generated worldwide sales of nearly 4 billion euros ($5 billion) last year, earlier failed to show overall heart benefits in a large clinical study.
However, a section of that trial suggests it could slow the thickening of arteries - a process known as atherosclerosis - that can raise the risk of heart attack and strokes, Dr Eva Lonn of Canada's McMaster University told the European Society of Cardiology annual meeting.
Lonn said Lantus appeared to slow the progression of atherosclerosis by 11 percent over five years in her analysis of 1,100 patients with early type-2 diabetes and cardiovascular risk factors.
http://www.tradearabia.com/news/HEAL_222300.html
I wonder who paid for the research...!
Lantus, which generated worldwide sales of nearly 4 billion euros ($5 billion) last year, earlier failed to show overall heart benefits in a large clinical study.
However, a section of that trial suggests it could slow the thickening of arteries - a process known as atherosclerosis - that can raise the risk of heart attack and strokes, Dr Eva Lonn of Canada's McMaster University told the European Society of Cardiology annual meeting.
Lonn said Lantus appeared to slow the progression of atherosclerosis by 11 percent over five years in her analysis of 1,100 patients with early type-2 diabetes and cardiovascular risk factors.
http://www.tradearabia.com/news/HEAL_222300.html
I wonder who paid for the research...!
